Cytiva To Invest $500 M to Expand Mfg Capacity

Cytiva, the new name of GE Healthcare Life Sciences following Danaher’s $21.4-billion acquisition of GE Healthcare Life Sciences in April 2020, has announced plans to invest $500 million to expand its manufacturing capacity in products supporting biopharmaceutical production and to hire an additional 1,000 people.

Cytiva’s global product manufacturing and distribution network encompasses 13 sites across Asia, the Americas, and Europe. The investments, totaling around $500 million, will respond to in-region and for-region demand, support security of supply through dual manufacturing, and increase overall global capacity in key product areas. Cytiva also plans to hire nearly 1,000 people globally.

In Asia-Pacific, single-use capacity will triple through a partnership with Wego, a healthcare technology supplier in China, which is already producing consumables for Cytiva’s customers in the region.

Cell-culture media production will increase by expanding manufacturing lines and cleanroom space at the company’s site in Logan, Utah and by adding additional shifts and personnel. The company’s sites in Singapore and Pasching, Austria are increasing output through more personnel and additional work shifts. This follows a tenfold increase in powdered cell-culture media production announced in May 2018.

In addition, manufacturing capacity of Cytiva’s MabSelect and Capto chromatography product platforms has doubled as part of $70-million-per-year (2017-2022) capacity gains and a facility modernization program at its Uppsala, Sweden site. The plant is now fully automated to allow continuous manufacturing. Other elements of that investment include: capacity extension of the company’s Sephadex resin; setting-up additional facilities for in-house manufacturing; and the development of automation and digitalization infrastructure.

Cytiva is also investing in a new facility in Grens, Switzerland to manufacture single-use kits for its Sepax and Sefia cell-processing systems for use in the production of cell and gene therapies

Source: Cytiva

Leave a Reply

Your email address will not be published. Required fields are marked *